ImmuCell Q1 2023 Earnings Report

ImmuCell EPS Results

• Actual EPS: -$0.30
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

ImmuCell Revenue Results

• Actual Revenue: $3.45 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

ImmuCell Announcement Details

• Quarter: Q1 2023
• Date: 5/11/2023
• Time: N/A

ImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.